Percheron Therapeutics (ASX:PER) appointed Eugene Kennedy as chief medical officer and Valentina Dubljevic as chief technology officer, according to a Tuesday filing with the Australian bourse.
These appointments align with the company's upcoming phase two trial of its lead program, HMBD-002, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.